The alcohol use disorder (AUD) market is projected to expand at a 12.1% compound annual growth rate (CAGR) from 2026 to 2036, driven by unmet clinical needs and the development of novel therapies targeting new mechanisms like the 5-HT3 pathway and NOP receptor. Key companies including Adial Pharmaceuticals and Eli Lilly are advancing promising drugs such as AD04 and Brenipatide, which are expected to reshape treatment options. Increased public awareness, reduced stigma, and regulatory approvals are boosting diagnosis and treatment adoption, particularly in the US where the market was valued at $1.1 billion in 2025. These innovations signal significant growth and improved care standards in the AUD treatment landscape over the next decade.
Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, gaining access to experimental drugs targeting mental health conditions like treatment-resistant depression. AtaiBeckley's lead drug, a DMT-based nasal sp...
Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...
